Curium Pharma is reportedly in advanced discussions to acquire radiopharmaceutical company Lantheus Holdings in a transaction valued at approximately $7 billion, according to Bloomberg. The potential acquisition would bring together two major businesses operating across nuclear medicine, diagnostic imaging and targeted radiopharmaceutical development.
Under the structure reportedly being discussed, Lantheus shareholders would receive approximately $102 per share in cash at closing. Investors could also receive up to an additional $12.50 per share through contingent value rights, bringing the maximum potential consideration to approximately $114.50 per share if the specified conditions are ultimately satisfied.
The upfront portion of the transaction would reportedly value Lantheus at approximately $7 billion, while the additional contingent payments could increase the total value to roughly $8 billion. The use of contingent consideration could help bridge differences between the parties over the present value of Lantheus’ pipeline, future product performance or the likelihood of achieving important regulatory and commercial milestones.
Contingent value rights, commonly known as CVRs, give acquired-company shareholders the opportunity to receive additional payments after a transaction closes. The payments are typically tied to clearly defined events, such as a drug receiving regulatory approval, reaching a particular level of sales or achieving another product-development milestone within a specified period.
CVRs can allow a buyer to limit the amount paid upfront for assets whose future value remains uncertain while giving the seller’s shareholders additional upside if those assets perform successfully. However, shareholders may receive less than the maximum stated transaction value when the required milestones are not achieved, are delayed beyond the agreed deadline or become subject to disputes over whether the conditions were satisfied.
No final agreement has been reached, and the reported terms could change as negotiations continue. The discussions may also end without a transaction, particularly if the companies cannot agree on valuation, financing, regulatory protections or the conditions attached to the contingent consideration. Neither Curium nor Lantheus has formally confirmed the potential acquisition.
Lantheus develops diagnostic imaging agents and radiopharmaceutical products used to detect, evaluate and manage serious diseases. Its portfolio includes products used in prostate cancer imaging and neurological applications involving Alzheimer’s disease, along with other agents supporting physicians in identifying disease and making treatment decisions.
Radiopharmaceuticals contain radioactive isotopes that can be used for either diagnosis or therapy. Diagnostic products are designed to reveal biological activity through imaging technologies such as positron emission tomography, allowing physicians to identify disease-related changes that may not be visible through conventional anatomical imaging alone.
Therapeutic radiopharmaceuticals are designed to deliver radiation more directly to cancer cells or other disease targets. This approach may allow treatment to concentrate on affected tissue while limiting exposure to surrounding healthy areas, although its effectiveness and safety depend on the specific isotope, targeting mechanism and disease involved.
Curium also operates in nuclear medicine and provides products used in diagnostic imaging and targeted radiopharmaceutical applications. The company is backed by private equity firm CapVest Partners, which could use the acquisition to create a larger and more diversified radiopharmaceutical platform with expanded commercial, manufacturing and research capabilities.
A combination could give the companies greater scale across product development, isotope sourcing, manufacturing, distribution and relationships with hospitals and imaging centers. These capabilities are especially important in nuclear medicine because many radiopharmaceutical products have limited shelf lives and must be manufactured, transported and administered within tightly controlled timeframes.
The proposed acquisition could also strengthen Curium’s presence in the United States and expand its exposure to disease areas attracting substantial pharmaceutical investment. Interest in radiopharmaceuticals has increased as drug developers seek more precise approaches to diagnosing and treating cancer and neurological conditions.
Large pharmaceutical companies and specialized healthcare investors have pursued radiopharmaceutical assets because the field combines imaging, precision medicine and targeted therapy. The market has also benefited from advances in biomarker identification, isotope production and drug-delivery technologies that make it possible to target specific biological characteristics of a disease.
However, operating in the sector requires specialized manufacturing facilities, regulatory expertise and reliable access to radioactive isotopes. Companies must also manage complex distribution networks because some products lose effectiveness quickly as their radioactive materials decay.
The possible acquisition would therefore involve both significant growth opportunities and operational challenges. Curium would need to integrate Lantheus’ products, employees, manufacturing relationships and development programs while maintaining the consistent delivery and regulatory compliance required across the nuclear medicine supply chain.
A deal of this size could also face review from competition authorities, particularly where the companies have overlapping products, development programs or commercial relationships. Regulators could examine whether the combination would reduce competition in specific diagnostic imaging or radiopharmaceutical markets.
Financing would represent another important consideration. Curium’s private equity backing may allow the company to combine sponsor equity with debt financing, although the final capital structure has not been reported. The amount of leverage used could influence the combined company’s ability to invest in research, manufacturing capacity and future acquisitions following the transaction.
For Lantheus shareholders, the reported $102-per-share cash payment would provide immediate value, while the CVR would preserve some exposure to the future performance of selected assets. The attractiveness of the proposal would depend not only on the headline value but also on the probability, timing and enforceability of the milestones connected to the additional $12.50 payment.
The potential acquisition remains based on unnamed-source reporting and should not be treated as a completed or formally announced transaction. Until Curium and Lantheus enter into a definitive agreement, the valuation, payment structure, and expected closing conditions remain subject to change.
